A Novel Treatment Strategy for Patients with Intermediate-Stage HCC Who Are Not Suitable for TACE: Upfront Systemic Therapy Followed by Curative Conversion.
作者信息
Kudo Masatoshi
机构信息
Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Osaka-Sayama, Japan.
出版信息
Liver Cancer. 2021 Oct 12;10(6):539-544. doi: 10.1159/000519749. eCollection 2021 Nov.
Abstract
摘要
相似文献
1
A Novel Treatment Strategy for Patients with Intermediate-Stage HCC Who Are Not Suitable for TACE: Upfront Systemic Therapy Followed by Curative Conversion.一种针对不适合经动脉化疗栓塞术（TACE）的中期肝癌患者的新型治疗策略：先行全身治疗，随后进行根治性转化治疗。
Liver Cancer. 2021 Oct 12;10(6):539-544. doi: 10.1159/000519749. eCollection 2021 Nov.
2
Atezolizumab plus Bevacizumab Followed by Curative Conversion (ABC Conversion) in Patients with Unresectable, TACE-Unsuitable Intermediate-Stage Hepatocellular Carcinoma.阿替利珠单抗联合贝伐珠单抗序贯根治性转化（ABC转化）用于不可切除、不适合经动脉化疗栓塞术的中期肝细胞癌患者
Liver Cancer. 2022 Jul 27;11(5):399-406. doi: 10.1159/000526163. eCollection 2022 Sep.
3
Atezolizumab plus bevacizumab versus sorafenib or atezolizumab alone for unresectable hepatocellular carcinoma: A systematic review.阿替利珠单抗联合贝伐单抗对比索拉非尼或单用阿替利珠单抗治疗不可切除肝细胞癌的系统评价
World J Gastrointest Oncol. 2021 Nov 15;13(11):1813-1832. doi: 10.4251/wjgo.v13.i11.1813.
4
Efficacy of sorafenib in intermediate-stage hepatocellular carcinoma patients refractory to transarterial chemoembolization.索拉非尼对经动脉化疗栓塞术难治的中期肝细胞癌患者的疗效。
Oncology. 2014;87(6):330-41. doi: 10.1159/000365993. Epub 2014 Sep 6.
5
Treatment algorithm for intermediate and advanced stage hepatocellular carcinoma: Korea.中晚期肝细胞癌治疗算法：韩国。
Oncology. 2011;81 Suppl 1:141-7. doi: 10.1159/000333277. Epub 2011 Dec 22.
6
Novel biomarkers GEP/ABCB5 regulate response to adjuvant transarterial chemoembolization after curative hepatectomy for hepatocellular carcinoma.新型生物标志物 GEP/ABCB5 调节肝癌根治性肝切除术后辅助经动脉化疗栓塞的反应。
Hepatobiliary Pancreat Dis Int. 2018 Dec;17(6):524-530. doi: 10.1016/j.hbpd.2018.10.003. Epub 2018 Oct 29.
7
Effectiveness of Sorafenib in Patients with Transcatheter Arterial Chemoembolization (TACE) Refractory and Intermediate-Stage Hepatocellular Carcinoma.索拉非尼在经动脉化疗栓塞术（TACE）难治性和中期肝细胞癌患者中的疗效
Liver Cancer. 2015 Dec;4(4):253-62. doi: 10.1159/000367743. Epub 2015 Oct 21.
8
Lenvatinib for Hepatocellular Carcinoma: A Literature Review.乐伐替尼用于肝细胞癌：文献综述
Pharmaceuticals (Basel). 2021 Jan 6;14(1):36. doi: 10.3390/ph14010036.
9
Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: available evidence and expert opinion on the use of transarterial chemoembolization.中晚期肝细胞癌治疗策略的演进：经动脉化疗栓塞治疗的现有证据和专家意见
Cancer Treat Rev. 2011 May;37(3):212-20. doi: 10.1016/j.ctrv.2010.07.006. Epub 2010 Aug 17.
10
Curative therapies are superior to standard of care (transarterial chemoembolization) for intermediate stage hepatocellular carcinoma.在中期肝细胞癌中，治疗性疗法优于标准治疗（经动脉化疗栓塞）。
Liver Int. 2017 Mar;37(3):423-433. doi: 10.1111/liv.13242. Epub 2016 Oct 2.
引用本文的文献
1
Screening Candidates for Conversion Therapy in Unresectable Hepatocellular Carcinoma Patients After Tyrosine Kinase Inhibitor Plus PD-1/PD-L1 Antibody Therapy: A Multicenter Retrospective Study.酪氨酸激酶抑制剂联合PD-1/PD-L1抗体治疗后不可切除肝细胞癌患者转化治疗候选者的筛选：一项多中心回顾性研究
J Hepatocell Carcinoma. 2025 Aug 25;12:1921-1941. doi: 10.2147/JHC.S523476. eCollection 2025.
2
Prognostic Value of Clinical Complete Response for Patients with Initially Unresectable Hepatocellular Carcinoma after Conversion with Triple Therapy.三联疗法转化后初始不可切除肝细胞癌患者临床完全缓解的预后价值
Liver Cancer. 2025 Jan 21;14(4):420-434. doi: 10.1159/000543602. eCollection 2025 Aug.
3
Multidisciplinary strategies including local treatment to achieve drug-free status after atezolizumab plus bevacizumab treatment in hepatocellular carcinoma.多学科策略，包括局部治疗，以在肝细胞癌患者接受阿替利珠单抗加贝伐单抗治疗后实现无药状态。
Oncol Lett. 2025 Jul 31;30(4):466. doi: 10.3892/ol.2025.15212. eCollection 2025 Oct.
4
Role of immune checkpoint inhibitor combinations in resectable and unresectable, embolization-eligible hepatocellular carcinoma.免疫检查点抑制剂联合疗法在可切除和不可切除、适合栓塞治疗的肝细胞癌中的作用
Ther Adv Med Oncol. 2025 Jul 24;17:17588359251357719. doi: 10.1177/17588359251357719. eCollection 2025.
5
TACE Combined with Lenvatinib-PD-1 Versus TACE Monotherapy as Conversion Therapy Before Liver Resection in Unresectable Hepatocellular Carcinoma: A Retrospective, Propensity Score Matching Study.TACE联合乐伐替尼-PD-1与单纯TACE作为不可切除肝细胞癌肝切除术前转化治疗的比较：一项回顾性倾向评分匹配研究
J Hepatocell Carcinoma. 2025 Jul 22;12:1527-1540. doi: 10.2147/JHC.S517855. eCollection 2025.
6
A Case of Hepatocellular Carcinoma in a Patient with Idiopathic Forearm Arteriovenous Fistula.一例患有特发性前臂动静脉瘘的肝细胞癌患者
Case Rep Gastroenterol. 2025 Mar 20;19(1):173-183. doi: 10.1159/000544101. eCollection 2025 Jan-Dec.
7
Optimal sequencing of locoregional and systemic therapies for intermediate and advanced hepatocellular carcinoma: a network meta-analysis.中晚期肝细胞癌局部区域和全身治疗的最佳序贯：一项网状Meta分析。
J Cancer Res Clin Oncol. 2025 Jun 25;151(6):196. doi: 10.1007/s00432-025-06233-7.
8
Systemic Therapy Combined with Locoregional Therapy in Intermediate-stage Hepatocellular Carcinoma.全身治疗联合局部区域治疗用于中期肝细胞癌
Interv Radiol (Higashimatsuyama). 2024 Dec 13;10:e20230035. doi: 10.22575/interventionalradiology.2023-0035. eCollection 2025 Mar 28.
9
Lenvatinib plus Pembrolizumab Combined with Transarterial Chemoembolization in Intermediate-Stage Hepatocellular Carcinoma.仑伐替尼联合帕博利珠单抗与经动脉化疗栓塞术治疗中期肝细胞癌
Liver Cancer. 2024 Dec 20;14(1):1-7. doi: 10.1159/000543245. eCollection 2025 Mar.
10
Proposal of discontinuation criteria of atezolizumab plus bevacizumab after curative conversion therapy for unresectable early-to-intermediate-stage hepatocellular carcinoma: a multicenter proof-of-concept study.不可切除的早中期肝细胞癌根治性转化治疗后阿替利珠单抗联合贝伐单抗停药标准的提议：一项多中心概念验证研究
J Gastroenterol. 2025 Jun;60(6):738-753. doi: 10.1007/s00535-025-02233-z. Epub 2025 Mar 7.
本文引用的文献
1
Management of Hepatocellular Carcinoma in Japan: JSH Consensus Statements and Recommendations 2021 Update.日本肝细胞癌的管理：2021年更新版日本肝脏学会共识声明与建议
Liver Cancer. 2021 Jun;10(3):181-223. doi: 10.1159/000514174. Epub 2021 May 19.
2
Updated treatment recommendations for hepatocellular carcinoma (HCC) from the ESMO Clinical Practice Guidelines.欧洲肿瘤内科学会（ESMO）临床实践指南中肝细胞癌（HCC）的更新治疗建议。
Ann Oncol. 2021 Jun;32(6):801-805. doi: 10.1016/j.annonc.2021.02.014. Epub 2021 Mar 5.
3
Lenvatinib-Transarterial Chemoembolization Sequential Therapy as an Effective Treatment at Progression during Lenvatinib Therapy for Advanced Hepatocellular Carcinoma.乐伐替尼-经动脉化疗栓塞序贯疗法作为晚期肝细胞癌乐伐替尼治疗进展期的有效治疗方法
Liver Cancer. 2020 Dec;9(6):756-770. doi: 10.1159/000510299. Epub 2020 Oct 30.
4
A Changing Paradigm for the Treatment of Intermediate-Stage Hepatocellular Carcinoma: Asia-Pacific Primary Liver Cancer Expert Consensus Statements.中期肝细胞癌治疗模式的转变：亚太地区原发性肝癌专家共识声明
Liver Cancer. 2020 Jun;9(3):245-260. doi: 10.1159/000507370. Epub 2020 May 13.
5
Trial Design and Endpoints in Hepatocellular Carcinoma: AASLD Consensus Conference.肝细胞癌的试验设计与终点：美国肝病研究学会共识会议
Hepatology. 2021 Jan;73 Suppl 1:158-191. doi: 10.1002/hep.31327. Epub 2020 Sep 9.
6
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma.阿替利珠单抗联合贝伐珠单抗治疗不可切除肝细胞癌。
N Engl J Med. 2020 May 14;382(20):1894-1905. doi: 10.1056/NEJMoa1915745.
7
A New Era in Systemic Therapy for Hepatocellular Carcinoma: Atezolizumab plus Bevacizumab Combination Therapy.肝细胞癌全身治疗的新时代：阿替利珠单抗联合贝伐珠单抗联合疗法。
Liver Cancer. 2020 Apr;9(2):119-137. doi: 10.1159/000505189. Epub 2020 Mar 5.
8
Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial.随机、多中心前瞻性试验：比较经动脉化疗栓塞（TACE）联合索拉非尼与单纯 TACE 治疗肝细胞癌患者的疗效：TACTICS 试验。
Gut. 2020 Aug;69(8):1492-1501. doi: 10.1136/gutjnl-2019-318934. Epub 2019 Dec 4.
9
A New Treatment Option for Intermediate-Stage Hepatocellular Carcinoma with High Tumor Burden: Initial Lenvatinib Therapy with Subsequent Selective TACE.一种针对高肿瘤负荷中期肝细胞癌的新治疗选择：初始仑伐替尼治疗后序贯选择性经动脉化疗栓塞术
Liver Cancer. 2019 Oct;8(5):299-311. doi: 10.1159/000502905. Epub 2019 Sep 18.
10
Lenvatinib as an Initial Treatment in Patients with Intermediate-Stage Hepatocellular Carcinoma Beyond Up-To-Seven Criteria and Child-Pugh A Liver Function: A Proof-Of-Concept Study.乐伐替尼用于超出七项标准且肝功能为Child-Pugh A级的中期肝细胞癌患者的初始治疗：一项概念验证研究。
Cancers (Basel). 2019 Jul 31;11(8):1084. doi: 10.3390/cancers11081084.
Zotero 插件